Bernhardt George Zeiher

Title: Bernhardt George Zeiher: Innovator in Pharmaceutical Treatments

Introduction

Bernhardt George Zeiher is a notable inventor based in Surrey, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of infections. His innovative approach has led to the development of a unique dosage regimen for a tiacumicin compound.

Latest Patents

Zeiher holds a patent for a dosage regimen for a tiacumicin compound. This patent outlines a method for using the tiacumicin compound in the oral treatment of Clostridium difficile infections (CDI) and associated diseases (CDAD). The regimen includes an initial treatment of 200 mg of the tiacumicin compound administered twice a day, followed by monitoring the patient's response and adjusting the treatment accordingly. This innovative approach aims to reduce recurrence in patients suffering from CDI or CDAD.

Career Highlights

Zeiher is associated with Astellas Pharma Europe Ltd., where he has been instrumental in advancing pharmaceutical research and development. His work focuses on improving treatment protocols and enhancing patient outcomes through innovative drug regimens.

Collaborations

Zeiher has collaborated with notable colleagues, including Andreas Johannis Karas and Christopher Mark Longshaw. These partnerships have contributed to the successful development of his patented treatment methods.

Conclusion

Bernhardt George Zeiher's contributions to pharmaceutical innovations, particularly in the treatment of CDI and CDAD, highlight his role as a key inventor in the field. His work continues to impact patient care positively.